Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
24 juil. 2019 09h25 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative...
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
07 janv. 2019 08h39 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
16 mai 2018 08h00 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
09 avr. 2018 08h00 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., April 09, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
04 avr. 2018 08h00 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Announces Close of Convertible Note Financing
03 avr. 2018 13h26 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., April 03, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26 déc. 2017 11h41 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26 déc. 2017 08h00 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
07 déc. 2017 08h30 HE
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
17 oct. 2017 08h00 HE
|
AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant...